Switch to:
Also traded in: Argentina, Brazil, Chile, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt N/A
JNJ's Cash to Debt is ranked higher than
83% of the 761 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.46 vs. JNJ: N/A )
Ranked among companies with meaningful Cash to Debt only.
JNJ' s Cash to Debt Range Over the Past 10 Years
Min: 0.62  Med: 1.55 Max: 6.01
Current: N/A
0.62
6.01
Equity to Asset 0.53
JNJ's Equity to Asset is ranked lower than
63% of the 700 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.62 vs. JNJ: 0.53 )
Ranked among companies with meaningful Equity to Asset only.
JNJ' s Equity to Asset Range Over the Past 10 Years
Min: 0.5  Med: 0.55 Max: 0.66
Current: 0.53
0.5
0.66
Interest Coverage 50.48
JNJ's Interest Coverage is ranked higher than
59% of the 458 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 24.68 vs. JNJ: 50.48 )
Ranked among companies with meaningful Interest Coverage only.
JNJ' s Interest Coverage Range Over the Past 10 Years
Min: 28.29  Med: 36.54 Max: 208.73
Current: 50.48
28.29
208.73
F-Score: 5
Z-Score: 5.40
M-Score: -2.70
WACC vs ROIC
8.12%
26.95%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 25.89
JNJ's Operating margin (%) is ranked higher than
88% of the 707 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.77 vs. JNJ: 25.89 )
Ranked among companies with meaningful Operating margin (%) only.
JNJ' s Operating margin (%) Range Over the Past 10 Years
Min: 22.36  Med: 25.14 Max: 28.2
Current: 25.89
22.36
28.2
Net-margin (%) 21.92
JNJ's Net-margin (%) is ranked higher than
88% of the 710 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.28 vs. JNJ: 21.92 )
Ranked among companies with meaningful Net-margin (%) only.
JNJ' s Net-margin (%) Range Over the Past 10 Years
Min: 14.87  Med: 20.07 Max: 21.99
Current: 21.92
14.87
21.99
ROE (%) 21.88
JNJ's ROE (%) is ranked higher than
85% of the 739 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.27 vs. JNJ: 21.88 )
Ranked among companies with meaningful ROE (%) only.
JNJ' s ROE (%) Range Over the Past 10 Years
Min: 17.02  Med: 23.79 Max: 30.17
Current: 21.88
17.02
30.17
ROA (%) 11.69
JNJ's ROA (%) is ranked higher than
82% of the 763 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.85 vs. JNJ: 11.69 )
Ranked among companies with meaningful ROA (%) only.
JNJ' s ROA (%) Range Over the Past 10 Years
Min: 8.93  Med: 12.96 Max: 17.08
Current: 11.69
8.93
17.08
ROC (Joel Greenblatt) (%) 90.55
JNJ's ROC (Joel Greenblatt) (%) is ranked higher than
91% of the 755 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.64 vs. JNJ: 90.55 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
JNJ' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 65.66  Med: 87.89 Max: 114.87
Current: 90.55
65.66
114.87
Revenue Growth (3Y)(%) 1.40
JNJ's Revenue Growth (3Y)(%) is ranked lower than
65% of the 593 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.10 vs. JNJ: 1.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
JNJ' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 1.4  Med: 7.20 Max: 14.8
Current: 1.4
1.4
14.8
EBITDA Growth (3Y)(%) 9.30
JNJ's EBITDA Growth (3Y)(%) is ranked higher than
53% of the 543 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.90 vs. JNJ: 9.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
JNJ' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -6.6  Med: 10.00 Max: 17.4
Current: 9.3
-6.6
17.4
EPS Growth (3Y)(%) 12.40
JNJ's EPS Growth (3Y)(%) is ranked higher than
58% of the 496 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.40 vs. JNJ: 12.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
JNJ' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -8.6  Med: 10.90 Max: 20.2
Current: 12.4
-8.6
20.2
» JNJ's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-07-14)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2015

JNJ Guru Trades in Q2 2015

David Dreman 6,648 sh (New)
Sarah Ketterer 1,207,926 sh (+41.27%)
John Rogers 782,026 sh (+19.02%)
Manning & Napier Advisors, Inc 3,292,140 sh (+17.49%)
Paul Tudor Jones 63,433 sh (+13.16%)
John Buckingham 63,439 sh (+2.51%)
Ruane Cunniff 77,357 sh (+1.87%)
Mairs and Power 2,158,264 sh (+1.86%)
Ken Fisher 10,641,756 sh (+1.77%)
Jeff Auxier 91,926 sh (+0.27%)
Richard Pzena 1,174,169 sh (+0.01%)
T Rowe Price Equity Income Fund 4,633,000 sh (unchged)
John Hussman 1,325 sh (unchged)
Richard Snow 3,270 sh (unchged)
Robert Olstein 71,000 sh (unchged)
Tweedy Browne Global Value 865,835 sh (unchged)
Michael Price 25,000 sh (unchged)
RS Investment Management 8,578 sh (unchged)
Warren Buffett 327,100 sh (unchged)
Tom Gayner 574,200 sh (unchged)
Prem Watsa 82,850 sh (unchged)
Jim Simons Sold Out
Joel Greenblatt Sold Out
Barrow, Hanley, Mewhinney & Strauss 15,632,757 sh (-0.28%)
First Eagle Investment 1,610,098 sh (-1.09%)
Murray Stahl 29,841 sh (-2.72%)
Jeremy Grantham 12,907,199 sh (-2.73%)
Tweedy Browne 3,918,801 sh (-3.38%)
PRIMECAP Management 11,370,350 sh (-4.12%)
Dodge & Cox 38,235 sh (-4.38%)
Mario Gabelli 315,150 sh (-5.40%)
Richard Perry 292,729 sh (-6.36%)
Yacktman Fund 3,500,000 sh (-10.26%)
Donald Yacktman 7,441,948 sh (-11.75%)
Yacktman Focused Fund 2,500,000 sh (-16.67%)
Pioneer Investments 2,068,266 sh (-21.14%)
Ray Dalio 194,993 sh (-27.27%)
» More
Q3 2015

JNJ Guru Trades in Q3 2015

Charles Brandes 118,509 sh (New)
Jim Simons 392,000 sh (New)
John Burbank 32,624 sh (New)
Louis Moore Bacon 63,428 sh (New)
Chuck Royce 9,000 sh (New)
Manning & Napier Advisors, Inc 4,406,762 sh (+33.86%)
Sarah Ketterer 1,593,359 sh (+31.91%)
RS Investment Management 10,457 sh (+21.90%)
Jeff Auxier 110,226 sh (+19.91%)
Pioneer Investments 2,381,190 sh (+15.13%)
John Rogers 884,154 sh (+13.06%)
Yacktman Focused Fund 2,600,000 sh (+4.00%)
Yacktman Fund 3,600,000 sh (+2.86%)
John Buckingham 64,896 sh (+2.30%)
Donald Yacktman 7,560,334 sh (+1.59%)
Tom Gayner 582,200 sh (+1.39%)
Murray Stahl 30,179 sh (+1.13%)
Mairs and Power 2,181,707 sh (+1.09%)
T Rowe Price Equity Income Fund 4,672,800 sh (+0.86%)
Mario Gabelli 317,847 sh (+0.86%)
Ken Fisher 10,689,483 sh (+0.45%)
John Hussman 1,325 sh (unchged)
Prem Watsa 82,850 sh (unchged)
Richard Snow 3,270 sh (unchged)
Robert Olstein 71,000 sh (unchged)
Richard Perry 292,729 sh (unchged)
Tweedy Browne Global Value 865,835 sh (unchged)
David Carlson 460,000 sh (unchged)
Michael Price 25,000 sh (unchged)
Warren Buffett 327,100 sh (unchged)
Richard Pzena 1,174,169 sh (unchged)
David Dreman Sold Out
Ruane Cunniff 76,400 sh (-1.24%)
Barrow, Hanley, Mewhinney & Strauss 15,399,839 sh (-1.49%)
First Eagle Investment 1,585,928 sh (-1.50%)
Tweedy Browne 3,855,936 sh (-1.60%)
Dodge & Cox 36,935 sh (-3.40%)
PRIMECAP Management 10,575,867 sh (-6.99%)
Jeremy Grantham 11,529,743 sh (-10.67%)
Ray Dalio 167,593 sh (-14.05%)
Paul Tudor Jones 47,878 sh (-24.52%)
» More
Q4 2015

JNJ Guru Trades in Q4 2015

Joel Greenblatt 39,586 sh (New)
John Hussman 26,325 sh (+1886.79%)
John Burbank 68,755 sh (+110.75%)
First Eagle Investment 3,032,177 sh (+91.19%)
Jim Simons 655,300 sh (+67.17%)
Pioneer Investments 3,824,174 sh (+60.60%)
Charles Brandes 151,094 sh (+27.50%)
Mario Gabelli 332,287 sh (+4.54%)
Tom Gayner 605,200 sh (+3.95%)
John Buckingham 65,746 sh (+1.31%)
Ken Fisher 10,815,964 sh (+1.18%)
Mairs and Power 2,184,308 sh (+0.12%)
Richard Pzena 1,174,524 sh (+0.03%)
Prem Watsa 82,850 sh (unchged)
Robert Olstein 71,000 sh (unchged)
David Carlson 460,000 sh (unchged)
Richard Perry 292,729 sh (unchged)
Tweedy Browne Global Value 865,835 sh (unchged)
Warren Buffett 327,100 sh (unchged)
Michael Price 25,000 sh (unchged)
Yacktman Fund 3,600,000 sh (unchged)
T Rowe Price Equity Income Fund 4,672,800 sh (unchged)
Chuck Royce 9,000 sh (unchged)
Louis Moore Bacon Sold Out
PRIMECAP Management 10,543,562 sh (-0.31%)
Richard Snow 3,260 sh (-0.31%)
Barrow, Hanley, Mewhinney & Strauss 15,342,046 sh (-0.38%)
Murray Stahl 29,941 sh (-0.79%)
Paul Tudor Jones 46,483 sh (-2.91%)
Donald Yacktman 7,316,129 sh (-3.23%)
Yacktman Focused Fund 2,500,000 sh (-3.85%)
Dodge & Cox 35,435 sh (-4.06%)
Tweedy Browne 3,693,349 sh (-4.22%)
Jeff Auxier 105,426 sh (-4.35%)
John Rogers 831,664 sh (-5.94%)
Sarah Ketterer 1,497,289 sh (-6.03%)
RS Investment Management 9,592 sh (-8.27%)
Jeremy Grantham 9,970,431 sh (-13.52%)
Manning & Napier Advisors, Inc 3,769,800 sh (-14.45%)
Ruane Cunniff 64,753 sh (-15.24%)
Ray Dalio 109,693 sh (-34.55%)
» More
Q1 2016

JNJ Guru Trades in Q1 2016

Murray Stahl 30,774 sh (+2.78%)
Ken Fisher 10,854,263 sh (+0.35%)
Yacktman Fund 3,600,000 sh (unchged)
Tweedy Browne Global Value 865,835 sh (unchged)
Manning & Napier Advisors, Inc 3,543,252 sh (-6.01%)
Yacktman Focused Fund 2,300,000 sh (-8.00%)
T Rowe Price Equity Income Fund 3,961,300 sh (-15.23%)
» More
» Details

Insider Trades

Latest Guru Trades with JNJ

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Johnson & Johnson

Charles Brandes Comments on Johnson & Johnson - Oct 21, 2015

Healthcare giant Johnson & Johnson (NYSE:JNJ), which has diverse operations in pharmaceuticals, medical devices, biotechnology and consumer health, has faced potential competition in its pharmaceutical segment and lingering concerns over product recalls and manufacturing issues in its consumer segment. Nonetheless, we believe the company’s fundamentals remain attractive, including its strong competitive position and balance sheet, as well as a history of prudent capital deployment. The company generates approximately 70% of its revenues from businesses which command a #1 or #2 global market share, and 25% from products launched over the last five years. Speaking to the strength of its balance sheet, Johnson & Johnson is one of only four U.S. industrial companies with a AAA credit rating from both S&P and Moody’s.

From Charles Brandes (Trades, Portfolio)' third quarter 2015 commentary, Volatility: Misbehaving—In Action.

Check out Charles Brandes latest stock trades

Bill Frels Comments on Johnson & Johnson - Oct 20, 2014

Due to the expansion of its pharmaceutical business, Johnson & Johnson (JNJ) contributed better-than- expected performance during the period. Sales soared by 21% due to almost a dozen recent drug launches and improving profitability, which may support a robust acquisition strategy that could reportedly beat management’s goal of 4.5% growth in annual drug sales through 2017.

From Bill Frels (Trades, Portfolio)' Mairs & Power Growth Fund Q3 2014 Commentary.

Check out Bill Frels latest stock trades

Top Ranked Articles about Johnson & Johnson

How to Know When You Can Retire With Dividend Investing The ability to retire with dividend paying stocks is probably broader than you imagine
When I consider the topic of retirement the first thing that comes to mind is John Maynard Keynes' 1930 essay, “Economic Possibilities For Our Grandchildren.” Read more...
Periodic Payments vs. Lump Sum: When's the Right Time to Pull the Plug? A lump sum today may be better than annuity payments
When it comes to investing, the purpose is to receive the biggest reward possible given the prevailing circumstances at the time an investor decides to cash out. Generally, when investing, investors can take two approaches: buy a stock that guarantees periodic dividend payments or simply invest in a stock that promises a massive payout in the future in the form of capital gains. Read more...
Weekly CFO Sells Highlight: Facebook, Johnson & Johnson, PepsiCo Recent insider sales from company CFOs
According to GuruFocus Insider Data, the recent CFO sells were: Facebook Inc. (NASDAQ:FB), Johnson & Johnson (NYSE:JNJ) and PepsiCo Inc. (NYSE:PEP). Read more...
5 Guru Picks in Volatile Biotech Industry Johnson & Johnson and Merck each have the backing of more than 25 gurus
Biotech and pharmaceutical stocks made some of the biggest headlines this year, as 2015 saw massive waves of M&A activity, including the Pfizer (NYSE:PFE) and Allergan (NYSE:AGN) merger, the second-largest deal of all time valued at $160 billion. Other companies found themselves in the spotlight for less than desirable reasons, such as Valeant Pharmaceuticals (NYSE:VRX), whose stock has tanked in the past several months. Read more...
Mairs and Power Buys American Express, Pfizer in 3rd Quarter Firm increases stake in American Express by 87%
Mairs and Power (Trades, Portfolio) Inc. is an investment firm whose strength and success has resulted from applying a conservative growth investment approach consistently for over 70 years. The following are its most notable buys during the third quarter. Read more...
Charles Brandes Buys Stakes in Emerson Electric, Johnson & Johnson Guru adds more than 3 million shares to stake in Leucadia National
Charles Brandes (Trades, Portfolio), chairman of Brandes Investment Partners, the firm he founded in 1974, is an adherent of value investing, applying its principles to the portfolios that are managed by the firm as well as his own. The strategy has been successful. Last year, when many investors struggled in a challenging environment, Brandes’ U.S. Value Equity Fund produced positive returns exceeding 13%. Read more...
Charles Brandes Comments on Johnson & Johnson Guru stock highlight
Healthcare giant Johnson & Johnson (NYSE:JNJ), which has diverse operations in pharmaceuticals, medical devices, biotechnology and consumer health, has faced potential competition in its pharmaceutical segment and lingering concerns over product recalls and manufacturing issues in its consumer segment. Nonetheless, we believe the company’s fundamentals remain attractive, including its strong competitive position and balance sheet, as well as a history of prudent capital deployment. The company generates approximately 70% of its revenues from businesses which command a #1 or #2 global market share, and 25% from products launched over the last five years. Speaking to the strength of its balance sheet, Johnson & Johnson is one of only four U.S. industrial companies with a AAA credit rating from both S&P and Moody’s. Read more...
The Best Way to Reinvest Your Dividends for Retirement There are two primary strategies that can be implemented to reinvest dividends
The Best Way to Reinvest Your Dividends for Retirement Read more...
Joel Greenblatt Sells Johnson & Johnson, Flowserve A look at the Magic Formula inventor's largest trades
Joel Greenblatt (Trades, Portfolio) is the founder and managing partner of Gotham Asset Management LLC, which offers four diversified long/short equity mutual funds. Read more...
The Two Keys to the Magic Formula for Long-Term Investment Success Estimating future earnings growth is the second major key to successful long-term investing
Investing in anything comes with a degree of uncertainty because all investing returns happen in the future. And even though the future is unpredictable, the future is what everyone who invests is investing for. These realities present important challenges that every investor must face and deal with in order to succeed. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 20.36
JNJ's P/E(ttm) is ranked higher than
66% of the 540 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 28.10 vs. JNJ: 20.36 )
Ranked among companies with meaningful P/E(ttm) only.
JNJ' s P/E(ttm) Range Over the Past 10 Years
Min: 10.5  Med: 17.63 Max: 23.97
Current: 20.36
10.5
23.97
Forward P/E 16.08
JNJ's Forward P/E is ranked lower than
52% of the 69 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.85 vs. JNJ: 16.08 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 20.36
JNJ's PE(NRI) is ranked higher than
66% of the 536 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 28.01 vs. JNJ: 20.36 )
Ranked among companies with meaningful PE(NRI) only.
JNJ' s PE(NRI) Range Over the Past 10 Years
Min: 10.5  Med: 17.63 Max: 23.94
Current: 20.36
10.5
23.94
Price/Owner Earnings (ttm) 16.93
JNJ's Price/Owner Earnings (ttm) is ranked higher than
77% of the 261 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 32.99 vs. JNJ: 16.93 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
JNJ' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 9.82  Med: 16.91 Max: 25.3
Current: 16.93
9.82
25.3
P/B 4.37
JNJ's P/B is ranked lower than
70% of the 727 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.94 vs. JNJ: 4.37 )
Ranked among companies with meaningful P/B only.
JNJ' s P/B Range Over the Past 10 Years
Min: 2.68  Med: 3.71 Max: 5.64
Current: 4.37
2.68
5.64
P/S 4.50
JNJ's P/S is ranked lower than
66% of the 691 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.78 vs. JNJ: 4.50 )
Ranked among companies with meaningful P/S only.
JNJ' s P/S Range Over the Past 10 Years
Min: 2.17  Med: 3.23 Max: 4.55
Current: 4.5
2.17
4.55
PFCF 19.89
JNJ's PFCF is ranked higher than
63% of the 194 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 29.93 vs. JNJ: 19.89 )
Ranked among companies with meaningful PFCF only.
JNJ' s PFCF Range Over the Past 10 Years
Min: 10.28  Med: 16.52 Max: 24.65
Current: 19.89
10.28
24.65
POCF 16.30
JNJ's POCF is ranked higher than
55% of the 253 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 18.08 vs. JNJ: 16.30 )
Ranked among companies with meaningful POCF only.
JNJ' s POCF Range Over the Past 10 Years
Min: 8.98  Med: 13.18 Max: 18.34
Current: 16.3
8.98
18.34
EV-to-EBIT 15.76
JNJ's EV-to-EBIT is ranked higher than
63% of the 526 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.82 vs. JNJ: 15.76 )
Ranked among companies with meaningful EV-to-EBIT only.
JNJ' s EV-to-EBIT Range Over the Past 10 Years
Min: 7.8  Med: 13.00 Max: 18.2
Current: 15.76
7.8
18.2
EV-to-EBITDA 13.11
JNJ's EV-to-EBITDA is ranked higher than
64% of the 551 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.62 vs. JNJ: 13.11 )
Ranked among companies with meaningful EV-to-EBITDA only.
JNJ' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.7  Med: 11.00 Max: 14.1
Current: 13.11
6.7
14.1
PEG 3.49
JNJ's PEG is ranked lower than
67% of the 281 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.88 vs. JNJ: 3.49 )
Ranked among companies with meaningful PEG only.
JNJ' s PEG Range Over the Past 10 Years
Min: 1.17  Med: 1.66 Max: 26.05
Current: 3.49
1.17
26.05
Shiller P/E 23.66
JNJ's Shiller P/E is ranked higher than
78% of the 140 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 45.65 vs. JNJ: 23.66 )
Ranked among companies with meaningful Shiller P/E only.
JNJ' s Shiller P/E Range Over the Past 10 Years
Min: 15.48  Med: 20.74 Max: 29.83
Current: 23.66
15.48
29.83
Current Ratio 2.17
JNJ's Current Ratio is ranked lower than
55% of the 656 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.41 vs. JNJ: 2.17 )
Ranked among companies with meaningful Current Ratio only.
JNJ' s Current Ratio Range Over the Past 10 Years
Min: 1.2  Med: 1.93 Max: 2.49
Current: 2.17
1.2
2.49
Quick Ratio 1.88
JNJ's Quick Ratio is ranked higher than
52% of the 656 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.80 vs. JNJ: 1.88 )
Ranked among companies with meaningful Quick Ratio only.
JNJ' s Quick Ratio Range Over the Past 10 Years
Min: 0.94  Med: 1.59 Max: 2.18
Current: 1.88
0.94
2.18
Days Inventory 138.09
JNJ's Days Inventory is ranked lower than
63% of the 659 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 113.44 vs. JNJ: 138.09 )
Ranked among companies with meaningful Days Inventory only.
JNJ' s Days Inventory Range Over the Past 10 Years
Min: 100.19  Med: 105.89 Max: 137.6
Current: 138.09
100.19
137.6
Days Sales Outstanding 55.82
JNJ's Days Sales Outstanding is ranked higher than
67% of the 610 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 74.18 vs. JNJ: 55.82 )
Ranked among companies with meaningful Days Sales Outstanding only.
JNJ' s Days Sales Outstanding Range Over the Past 10 Years
Min: 53.94  Med: 57.41 Max: 61.4
Current: 55.82
53.94
61.4
Days Payable 112.77
JNJ's Days Payable is ranked higher than
70% of the 585 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 72.90 vs. JNJ: 112.77 )
Ranked among companies with meaningful Days Payable only.
JNJ' s Days Payable Range Over the Past 10 Years
Min: 98.27  Med: 111.33 Max: 147.94
Current: 112.77
98.27
147.94

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.68
JNJ's Dividend Yield is ranked higher than
81% of the 563 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.56 vs. JNJ: 2.68 )
Ranked among companies with meaningful Dividend Yield only.
JNJ' s Dividend Yield Range Over the Past 10 Years
Min: 1.78  Med: 2.84 Max: 3.84
Current: 2.68
1.78
3.84
Dividend Payout 0.54
JNJ's Dividend Payout is ranked higher than
95% of the 365 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.32 vs. JNJ: 0.54 )
Ranked among companies with meaningful Dividend Payout only.
JNJ' s Dividend Payout Range Over the Past 10 Years
Min: 0.34  Med: 0.40 Max: 0.65
Current: 0.54
0.34
0.65
Dividend Growth (3y) 7.10
JNJ's Dividend Growth (3y) is ranked lower than
51% of the 280 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.70 vs. JNJ: 7.10 )
Ranked among companies with meaningful Dividend Growth (3y) only.
JNJ' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 7  Med: 13.00 Max: 17.1
Current: 7.1
7
17.1
Forward Dividend Yield 2.84
JNJ's Forward Dividend Yield is ranked higher than
77% of the 527 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.60 vs. JNJ: 2.84 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 3.76
JNJ's Yield on cost (5-Year) is ranked higher than
79% of the 715 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.32 vs. JNJ: 3.76 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
JNJ' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 2.5  Med: 3.98 Max: 5.39
Current: 3.76
2.5
5.39

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 13.05
JNJ's Price/Tangible Book is ranked lower than
89% of the 675 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.58 vs. JNJ: 13.05 )
Ranked among companies with meaningful Price/Tangible Book only.
JNJ' s Price/Tangible Book Range Over the Past 10 Years
Min: 6.74  Med: 11.28 Max: 17.97
Current: 13.05
6.74
17.97
Price/Projected FCF 1.68
JNJ's Price/Projected FCF is ranked higher than
67% of the 298 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.83 vs. JNJ: 1.68 )
Ranked among companies with meaningful Price/Projected FCF only.
JNJ' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.98  Med: 1.44 Max: 3.6
Current: 1.68
0.98
3.6
Price/DCF (Earnings Based) 1.90
JNJ's Price/DCF (Earnings Based) is ranked lower than
66% of the 74 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.39 vs. JNJ: 1.90 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.39
JNJ's Price/Median PS Value is ranked lower than
63% of the 624 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.18 vs. JNJ: 1.39 )
Ranked among companies with meaningful Price/Median PS Value only.
JNJ' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.83  Med: 1.15 Max: 1.76
Current: 1.39
0.83
1.76
Price/Peter Lynch Fair Value 2.92
JNJ's Price/Peter Lynch Fair Value is ranked lower than
77% of the 174 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.59 vs. JNJ: 2.92 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
JNJ' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 1.28  Med: 1.83 Max: 3.85
Current: 2.92
1.28
3.85
Price/Graham Number 3.44
JNJ's Price/Graham Number is ranked lower than
71% of the 445 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.13 vs. JNJ: 3.44 )
Ranked among companies with meaningful Price/Graham Number only.
JNJ' s Price/Graham Number Range Over the Past 10 Years
Min: 1.99  Med: 3.21 Max: 5.43
Current: 3.44
1.99
5.43
Earnings Yield (Greenblatt) (%) 6.40
JNJ's Earnings Yield (Greenblatt) (%) is ranked higher than
74% of the 738 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.20 vs. JNJ: 6.40 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
JNJ' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 5.5  Med: 7.70 Max: 12.9
Current: 6.4
5.5
12.9
Forward Rate of Return (Yacktman) (%) 11.23
JNJ's Forward Rate of Return (Yacktman) (%) is ranked higher than
58% of the 315 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.27 vs. JNJ: 11.23 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
JNJ' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 1.8  Med: 14.30 Max: 18.6
Current: 11.23
1.8
18.6

More Statistics

Revenue(Mil) $70182
EPS $ 5.50
Beta0.88
Short Percentage of Float1.03%
52-Week Range $81.79 - 114.19
Shares Outstanding(Mil)2759.36

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil) 71,944 74,798 76,984
EPS($) 6.55 7.00 7.40
EPS without NRI($) 6.55 7.00 7.40

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:NYSE:PFE, XSWX:NOVN, NYSE:MRK, NYSE:BMY, XPAR:SAN » details
Traded in other countries:JNJ.Argentina, JNJB34.Brazil, JNJ.Chile, JNJ.Germany, JNJ.Mexico, JNJ.Switzerland, 0R34.UK,
Johnson & Johnson was incorporated in the State of New Jersey in 1887. The Company is engaged in the research and development, manufacture and sale of products in the health care field. It is a holding company, which has more than 275 operating companies conducting business in virtually all countries of the world. The Company's operating companies are organized into three business segments: Consumer, Pharmaceutical and Medical Devices and Diagnostics. The Consumer segment includes products used in the baby care, skin care, oral care, wound care and women's health care fields, as well as nutritional and over-the-counter pharmaceutical products. The Baby Care franchise includes the JOHNSON'S Baby line of products. The brands in the Skin Care franchise include the AVEENO; CLEAN & CLEAR; JOHNSON'S Adult; NEUTROGENA; RoC; LUBRIDERM; Beijing Dabao Cosmetics Co., Ltd.; and Vendome product lines. The Oral Care franchise includes the LISTERINE and REACH oral care lines of products. The brands in the Women"s Health franchise are the CAREFREE Pantiliners and STAYFREE sanitary protection products. The nutritional and over-the-counter lines include SPLENDA, No Calorie Sweetener; the family of TYLENOL acetaminophen products; SUDAFED cold, flu and allergy products; ZYRTEC allergy products; MOTRIN IB ibuprofen products; and PEPCID AC Acid Controller from Johnson & Johnson Merck Consumer Pharmaceuticals Co. The Pharmaceutical segment includes products in the following therapeutic areas: anti-infective, antipsychotic, cardiovascular, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, urology and virology. Key products in the Pharmaceutical segment include: REMICADE a treatment for a number of immune-mediated inflammatory diseases; SIMPONI (golimumab), a treatment for adults with moderate to severe rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis and moderately active to severely active ulcerative colitis; STELARA a treatment for adults with moderate to severe plaque psoriasis and active psoriatic arthritis; INCIVO for the treatment of hepatitis C; INTELENCE and PREZISTA, treatments for HIV/AIDS; CONCERTA extended-release tablets CII, a treatment for attention deficit hyperactivity disorder; INVEGA extended-release tablets, for the treatment of schizophrenia and schizoaffective disorder; INVEGA SUSTENNA/XEPLION, for the treatment of schizophrenia in adults; RISPERDAL CONSTA, for the treatment of schizophrenia and for the maintenance treatment of Bipolar I Disorder; VELCADE, a treatment for multiple myeloma; ZYTIGA, a treatment for metastatic castration-resistant prostate cancer; ACIPHEX/PARIET, a proton pump inhibitor co-marketed with Eisai Inc.; PROCRIT, to stimulate red blood cell production; and XARELTO, an oral anticoagulant for the prevention of deep vein thrombosis (DVT), which may cause to pulmonary embolism (PE) in patients undergoing hip or knee replace
» More Articles for JNJ

Headlines

Articles On GuruFocus.com
UnitedHealth’s Obamacare Changes to Affect Healthcare Sector Apr 27 2016 
Johnson & Johnson Beats 1st-Quarter Expectations, Improves Guidance Apr 27 2016 
How to Know When You Can Retire With Dividend Investing Apr 13 2016 
Periodic Payments vs. Lump Sum: When's the Right Time to Pull the Plug? Apr 07 2016 
Dividend and Value Opportunities in the Large-Cap Pharmaceutical Space Apr 05 2016 
Is Zimmer Biomet Worth the Risk? Apr 01 2016 
A Cheap Dividend Aristocrat Yielding Over 4% Mar 02 2016 
Weekly CFO Sells Highlight: Facebook, Johnson & Johnson, PepsiCo Feb 21 2016 
What To Do When The Stock Market Falls Feb 16 2016 
Tweedy Browne Trims Stakes in Financial Stocks Feb 12 2016 

More From Other Websites
[$$] Apple Tops ExxonMobil in Generous Dividends Apr 29 2016
Looking for dividends Apr 29 2016
Johnson & Johnson’s 1Q16 Valuation Cheat Sheet Apr 29 2016
Janssen Submits Application to U.S. FDA Seeking Approval of a Mebendazole Chewable Tablet for the... Apr 29 2016
Correction: Abbott-St Jude Acquisition story Apr 29 2016
Correction: Abbott-St Jude Acquisition story Apr 29 2016
Gilead Says European CHMP Adopts Positive Opinion For Its Odefsey For Treating HIV Apr 29 2016
Zacks Investment Ideas feature highlights: Visa, Johnson & Johnson and Snap-On Incorporated Apr 29 2016
Drug Stocks Q1 Earnings Preview: AEGR, AERI, MACK, PRTA Apr 29 2016
Gilead Disappoints, Harvoni Sales Drop 16% Apr 28 2016
Will Johnson & Johnson (JNJ) Stock Be Helped by Dividend Hike? Apr 28 2016
AbbVie forges deeper into cancer, as clock ticks for Humira Apr 28 2016
Johnson & Johnson hikes dividend at shareholders meeting Apr 28 2016
Johnson & Johnson hikes dividend at shareholders meeting Apr 28 2016
Johnson & Johnson Boosts Dividend By 6.7% Apr 28 2016
Biotech Boom May Continue Through Earnings Season Apr 28 2016
Johnson & Johnson Announces Dividend Increase of 6.7% Apr 28 2016
Johnson & Johnson raises quarterly dividend to 80 cents vs. 75 cents Apr 28 2016
10:31 am Johnson & Johnson increases quarterly dividend to $0.80/share from $0.75/share Apr 28 2016
Johnson & Johnson Announces Dividend Increase of 6.7% Apr 28 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK